Fallbericht mit Baricitinib

Psenak, O; Lilly Jahresbuch. 2019.

Anal Ureaplasma spp. positivity among HIV positive men who have sex with men may be associated with high-risk-type HPV infections.

Borena, W; Kruis, S; Kitchen, M; Taylor, N; Gisinger, M; Oberkofler, H; Stoiber, H; Zangerle, R; von Laer, D; Sarcletti, M INT J INFECT DIS. 2019; 84: 75-79.

Intense Uptake of Liposomal Curcumin by Multiple Myeloma Cell Lines: Comparison to Normal Lymphocytes, Red Blood Cells and Chronic Lymphocytic Leukemia Cells.

Bolger, GT; Licollari, A; Bagshaw, R; Tan, AM; Greil, R; Vcelar, B; Majeed, M; Sordillo, P ANTICANCER RES. 2019; 39(3): 1161-1168.

Next Generation Sequencing in AML-On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?

Leisch, M; Jansko, B; Zaborsky, N; Greil, R; Pleyer, L CANCERS. 2019; 11(2):

Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study.

Lang, D; Huemer, F; Rinnerthaler, G; Horner, A; Wass, R; Brehm, E; Akbari, K; Granitz, M; Hutarew, G; Kaiser, B; Greil, R; Lamprecht, B; Target Oncol. 2019; 14(6): 707-717.

Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma

Ludwig, H; Poenisch, W; Knop, S; Egle, A; Schreder, M; Lechner, D; Hajek, R; Gunsilius, E; Krenosz, KJ; Petzer, A; Weisel, K; Niederwieser, D; Einsele, H; Willenbacher, W; Melchardt, T; Greil, R; Zojer, N BRIT J CANCER. 2019; 121(9): 751-757.

BIRC3 Expression Predicts CLL Progression and Defines Treatment Sensitivity via Enhanced NF-κB Nuclear Translocation.

Asslaber, D; Wacht, N; Leisch, M; Qi, Y; Maeding, N; Hufnagl, C; Jansko, B; Zaborsky, N; Villunger, A; Hartmann, TN; Greil, R; Egle, A; Clin Cancer Res. 2019; 25(6):1901-1912

Plitidepsin: a potential new treatment for relapsed/refractory multiple myeloma.

Leisch, M; Egle, A; Greil, R; Future Oncol. 2019; 15(2):109-120

Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients.

Matikas, A; Foukakis, T; Moebus, V; Greil, R; Bengtsson, NO; Steger, GG; Untch, M; Johansson, H; Hellström, M; Malmström, P; Gnant, M; Loibl, S; Bergh, J; Ann Oncol. 2019; 30(1): 109-114.

Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer.

Huemer, F; Schlintl, V; Hecht, S; Hackl, H; Melchardt, T; Rinnerthaler, G; Greil, R; Weiss, L; Clin Colorectal Cancer. 2019; 18(2):159-166.e3